ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,282.70
      0.13%
      US Tech 100
      17,825.60
      0.33%
      Dow Jones
      39,142.23
      -1.33%
      Brent Oil
      67.075
      0.00%
      Bitcoin
      85,315.79
      0.98%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Halozyme Therapeutics Incorporated (HALO)

      7. Halozyme Therapeutics Incorporated (HALO) Financials

      Halozyme Therapeutics Incorporated

      Halozyme Therapeutics Incorporated (HALO)

      Halo Collective Inc
      58.79
      -0.03
      (-0.05%)
      Closed April 19 4:00PM
      Delayed by 15 minutes
      59.00
      0.21
      (0.36%)
      After Hours: 7:37PM
      Delayed by 15 minutes

      Halozyme Therapeutics Incorporated Financial Summary

      The current HALO market cap is 7.27B. The company's latest EPS is USD 3.6060 and P/E is 16.30.

      Income Statement

      Annual Quarterly
      Quarter End Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
      USD ($)USD ($)USD ($)USD ($)USD ($)
      Total Revenue 230.04M195.88M231.35M290.08M298.01M
      Operating Income 101.04M95.54M117.24M163.2M175.5M
      Net Income 85.39M76.82M93.25M137.01M137.01M
      Year End December 30 2024 20202021202220232024
      USD ($)USD ($)USD ($)USD ($)USD ($)
      Total Revenue 267.59M443.31M660.12M829.25M1.02B
      Operating Income 144.26M275.9M267.53M337.57M551.48M
      Net Income 129.09M402.71M202.13M281.59M444.09M

      Balance Sheet

      Annual Quarterly
      Quarter End Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
      USD ($)USD ($)USD ($)USD ($)USD ($)
      Total Assets 1.73B1.84B1.97B2.12B2.06B
      Total Liabilities 1.65B1.66B1.68B1.67B1.7B
      Total Equity 83.81M177.81M289.42M452.7M363.82M
      Year End December 30 2024 20202021202220232024
      USD ($)USD ($)USD ($)USD ($)USD ($)
      Total Assets 579.92M1.1B1.84B1.73B2.06B
      Total Liabilities 428.88M907.48M1.67B1.65B1.7B
      Total Equity 151.05M196.95M169.8M83.81M363.82M

      Cash Flow

      Annual Quarterly
      Quarter End Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
      USD ($)USD ($)USD ($)USD ($)USD ($)
      Operating 388.57M129.43M185.22M300.6M479.06M
      Investing -96.91M-82.68M-124.72M-292.2M-262.72M
      Financing -407.99M-489k8.99M27.55M-218.86M
      Year End December 30 2024 20202021202220232024
      USD ($)USD ($)USD ($)USD ($)USD ($)
      Operating 55.45M299.44M240.11M388.57M479.06M
      Investing 78.35M-406.29M-487.01M-96.91M-262.72M
      Financing -106.28M77.87M362.37M-407.99M-218.86M

      Stats and Ratios

      Market Cap 7.27B
      Price to Earnings Ratio 16.30
      Price to Sales Ratio 7.13
      Price to Cash Ratio 62.49
      Price to Book Ratio 19.9
      Dividend Yield -

      Share Statistics

      Shares Outstanding 123.15M
      Average Volume (1 week) 1.68M
      Average Volume (1 Month) 1.8M
      52 Week Change 53.45%
      52 Week High 66.00
      52 Week Low 37.73
      Spread (Intraday) 5.6 (8.89%)

      Company Info

      Company Name Halozyme Therapeutics Incorporated
      Address 1209 orange street
      wilmington, delaware 19801
      Website https://www.halozyme.com
      Industry biological pds,ex diagnstics (2836)

      Your Recent History

      NASDAQ
      HALO
      Halozyme Therapeutics
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads